Jing Yi

8.2k total citations · 3 hit papers
34 papers, 5.1k citations indexed

About

Jing Yi is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jing Yi has authored 34 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 14 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jing Yi's work include Cancer Immunotherapy and Biomarkers (6 papers), Wnt/β-catenin signaling in development and cancer (6 papers) and Lung Cancer Treatments and Mutations (5 papers). Jing Yi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Wnt/β-catenin signaling in development and cancer (6 papers) and Lung Cancer Treatments and Mutations (5 papers). Jing Yi collaborates with scholars based in United States, China and United Kingdom. Jing Yi's co-authors include Jie Wang, Alan Sandler, Keunchil Park, Achim Rittmeyer, Marcus Ballinger, Julien Mazières, Á. Artal, Daniel S. Chen, Wei Zou and Daniel Waterkamp and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Jing Yi

34 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

2016 2.1k citations Louis Fehrenbacher, Alexander I. Spira et al. The Lancet profile →
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

2012 970 citations Carol Aghajanian, Stephanie V. Blank et al. Journal of Clinical Oncology profile →
Cancer cell killing via ROS: To increase or decrease, that is the question

2008 640 citations Jie Wang, Jing Yi Cancer Biology & Therapy profile →

Peers

Jing Yi

ONCOL

PRM

IMMUN

Michele Orditura Italy

Yiping Zhang China

Gerrit Los United States

Christina M. Annunziata United States

Deborah A. Altomare United States

Agustin A. García United States

Ferdinando De Vita Italy

Gaetano Facchini Italy

Giovanna Damia Italy

Viviana Bazan Italy

Michele Orditura Italy

Jing Yi

3.4k ×1.1

ONCOL

2.1k ×1.2

PRM

1.9k ×1.6

228 ×0.3

677 ×0.9

IMMUN

Citations per year, relative to Jing Yi Jing Yi (= 1×) peers Michele Orditura

Countries citing papers authored by Jing Yi

Since Specialization

Citations

This map shows the geographic impact of Jing Yi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jing Yi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jing Yi more than expected).

Fields of papers citing papers by Jing Yi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jing Yi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jing Yi. The network helps show where Jing Yi may publish in the future.

Co-authorship network of co-authors of Jing Yi

This figure shows the co-authorship network connecting the top 25 collaborators of Jing Yi. A scholar is included among the top collaborators of Jing Yi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jing Yi. Jing Yi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yi, Jing, Li Li, Zhujun Yin, et al.. (2023). Polypeptide from Moschus Suppresses Lipopolysaccharide-Induced Inflammation by Inhibiting NF-κ B-ROS/NLRP3 Pathway. Chinese Journal of Integrative Medicine. 29(10). 895–904. 47 indexed citations

Yi, Jing, Tianhui Hu, Jun Yuan, et al.. (2023). Resveratrol protects against postmenopausal atherosclerosis progression through reducing PCSK9 expression via the regulation of the ERα-mediated signaling pathway. Biochemical Pharmacology. 211. 115541–115541. 13 indexed citations

Lü, Shun, Jian Fang, Ziping Wang, et al.. (2022). Results from the IMpower132 China cohort: Atezolizumab plus platinum‐based chemotherapy in advanced non‐small cell lung cancer. Cancer Medicine. 12(3). 2666–2676. 6 indexed citations

Gadgeel, Shirish M., Fred R. Hirsch, Keith M. Kerr, et al.. (2021). Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial. Clinical Lung Cancer. 23(1). 21–33. 13 indexed citations

Wang, Zhen, et al.. (2021). Analysis of CK5/6 and EGFR and Its Effect on Prognosis of Triple Negative Breast Cancer. Frontiers in Oncology. 10. 575317–575317. 12 indexed citations

Yi, Jing, Tianhui Hu, Chao Lin, et al.. (2019). Resveratrol downregulates PCSK9 expression and attenuates steatosis through estrogen receptor α-mediated pathway in L02 cells. European Journal of Pharmacology. 855. 216–226. 42 indexed citations

Bi, Cong, Yan Liao, Peibo Li, et al.. (2019). Pharmacodynamic effects of Dan-hong injection in rats with blood stasis syndrome. Biomedicine & Pharmacotherapy. 118. 109187–109187. 22 indexed citations

Yu, Ning, et al.. (2017). Real World Treatment Patterns Of Patients With Ovarian Cancer Receiving First Line Chemotherapy In The United States. Value in Health. 20(9). A473–A473. 2 indexed citations

Carmon, Kendra S., Xing Gong, Jing Yi, et al.. (2017). LGR5 receptor promotes cell–cell adhesion in stem cells and colon cancer cells via the IQGAP1–Rac1 pathway. Journal of Biological Chemistry. 292(36). 14989–15001. 60 indexed citations

10.

Fehrenbacher, Louis, Alexander I. Spira, Marcus Ballinger, et al.. (2016). Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. The Lancet. 387(10030). 1837–1846. 2112 indexed citations breakdown →

11.

Smith, David A., Johan Vansteenkiste, Louis Fehrenbacher, et al.. (2016). Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR).. Journal of Clinical Oncology. 34(15_suppl). 9028–9028. 22 indexed citations

12.

Yi, Jing, Kendra S. Carmon, Christine Crumbley, et al.. (2014). Aberrant RSPO3-LGR4 signaling in Keap1-deficient lung adenocarcinomas promotes tumor aggressiveness. Oncogene. 34(36). 4692–4701. 59 indexed citations

13.

Yi, Jing, Wei Xiong, Xing Gong, et al.. (2013). Analysis of LGR4 Receptor Distribution in Human and Mouse Tissues. PLoS ONE. 8(10). e78144–e78144. 50 indexed citations

14.

Aghajanian, Carol, Stephanie V. Blank, Barbara A. Goff, et al.. (2012). OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Journal of Clinical Oncology. 30(17). 2039–2045. 970 indexed citations breakdown →

15.

White, Darrell, et al.. (2012). Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer. 119(2). 339–347. 57 indexed citations

16.

Gong, Xing, Kendra S. Carmon, Qiushi Lin, et al.. (2012). LGR6 Is a High Affinity Receptor of R-Spondins and Potentially Functions as a Tumor Suppressor. PLoS ONE. 7(5). e37137–e37137. 98 indexed citations

17.

Jiang, Guojian, Xiaohui Xu, Jing Yi, Ruixin Wang, & Ting‐Jun Fan. (2011). Comparative studies on sorting cells from Artemia sinica at different developmental stages for in vitro cell culture. In Vitro Cellular & Developmental Biology - Animal. 47(5-6). 341–345. 4 indexed citations

18.

Sandler, Alan, Jing Yi, Suzanne E. Dahlberg, et al.. (2010). Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(9). 1416–1423. 125 indexed citations

19.

Kabbinavar, Fairooz F., Herbert I. Hurwitz, Jing Yi, Somnath Sarkar, & Oliver Rosen. (2008). Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials. Journal of Clinical Oncology. 27(2). 199–205. 135 indexed citations

20.

Wang, Jie & Jing Yi. (2008). Cancer cell killing via ROS: To increase or decrease, that is the question. Cancer Biology & Therapy. 7(12). 1875–1884. 640 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact